tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Trump’s Vaccine and Medication Advice: Potential Ripple Effects on Pharma Stocks

Trump’s Vaccine and Medication Advice: Potential Ripple Effects on Pharma Stocks

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

President Trump has posted a new announcement on Truth Social, the social media platform. He wrote:

“Pregnant Women, DON’T USE TYLENOL UNLESS ABSOLUTELY NECESSARY, DON’T GIVE TYLENOL TO YOUR YOUNG CHILD FOR VIRTUALLY ANY REASON, BREAK UP THE MMR SHOT INTO THREE TOTALLY SEPARATE SHOTS (NOT MIXED!), TAKE CHICKEN P SHOT SEPARATELY, TAKE HEPATITAS B SHOT AT 12 YEARS OLD, OR OLDER, AND, IMPORTANTLY, TAKE VACCINE IN 5 SEPARATE MEDICAL VISITS! President DJT”

How Will Trump’s Statement Affect the Stock Market?

This latest post has the potential to affect the stock market. That’s because Donald Trump’s social media post advising against the use of Tylenol and advocating for changes in vaccination schedules could potentially impact the stock prices of pharmaceutical companies like Johnson & Johnson, Merck & Company, and Pfizer Inc, as these companies are involved in the production of these medications and vaccines. The Health Care Select Sector SPDR Fund, Vanguard Health Care ETF, and iShares Biotechnology ETF, which include these companies in their portfolios, might also experience volatility due to shifts in investor sentiment and public perception influenced by Trump’s statements. Such public declarations can lead to increased scrutiny and debate over pharmaceutical practices, potentially affecting market confidence and stock valuations.

Here are some of the stocks that might be affected:
Johnson & Johnson ((JNJ)),
Merck & Company ((MRK)),
Pfizer Inc ((PFE)),
Health Care Select Sector SPDR Fund ((XLV)),
Vanguard Health Care ETF ((VHT)),
iShares Biotechnology ETF ((IBB)).

Disclaimer & DisclosureReport an Issue

1